Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 28, 2024
Daily News
November 28, 2024
- PhRMA Wants No Off-Year Price Cuts, Urges Japan Not to Backslide: Chair
November 28, 2024
- Scrap Off-Year Price Revisions, Smaller Japan Firms Face Uphill Battle: DPP Exec
November 28, 2024
- DPP Confirms Plan to Urge 4 Ministers to Scrap Off-Year Price Revisions
November 28, 2024
- Panel OKs 1-Year Extension of HPV Catch-Up Vaccinations, with Strings Attached
November 28, 2024
- Pfizer Files Migraine Drug Rimegepant in Japan
November 28, 2024
- Sakigake Tag Granted for Iclepertin, Brogidirsen
November 28, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…